Patients with polymyositis (PM) interstitial lung disease (ILD) vs dermatomyositis (DM)-ILD are more likely to respond to conventional treatment, suggests a recent study. However, clinical characteristics and serology do not otherwise predict response to therapy.
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
The oral pill fingolimod significantly reduces relapses vs interferon beta-1a in PARADIGMS, the first randomized controlled trial of fingolimod vs interferon beta-1a in paediatric multiple sclerosis (MS).
Children with polyarticular juvenile idiopathic arthritis (JIA), oligoarticular JIA and spondyloarthropathies (SpA) appear to have amplified exposure to gut bacterial products, highlighting the view that the intestine is a source of immune stimulation in JIA, a recent study has found.
An initial strategy of 1-year romosozumab followed by alendronate is superior over alendronate alone in reducing new vertebral fractures in postmenopausal women with osteoporosis at high risk for fracture, according to the ARCH* study.
There appears to be a paradox in the context of smoking and the risk of psoriatic arthritis (PsA), such that current smoking increases the risk of developing PsA in the general population but protects against the same risk among patients with psoriasis, according to a study.
Etoricoxib exhibits a central mode of action and enhances pain and function in patients with painful knew osteoarthritis (OA), as presented in a randomised, double-blind, placebo-controlled, two-way crossover, four-week treatment study.
The addition of supervised physiotherapy to usual care does not provide clinically important improvement in the management of simple ankle sprains in a general population of patients seeking hospital-based acute care, according to results of a recent randomized controlled trial.
The toxic side-effects of chemotherapy appear to be induced by cell-free chromatin (cfCh) fragments released from dying cells, triggering DNA damage, apoptosis and inflammation in healthy cells, thereby exaggerating or amplifying the toxic effects caused by the drugs themselves, according to a study.